Researchers with the U.S Department of Energy (DOE)’s Joint BioEnergy Institute (JBEI) have identified a potential new advanced biofuel that could replace today’s standard fuel for diesel engines but would be clean, green, renewable and produced in the United States. Using the tools of synthetic biology, a JBEI research team engineered strains of two microbes, a bacteria and a yeast, to produce a precursor to bisabolane, a member of the terpene class of chemical compounds that are found in plants and used in fragrances and flavorings. Preliminary tests by the team showed that bisabolane’s properties make it a promising biosynthetic alternative to Number 2 (D2) diesel fuel. 

“This is the first report of bisabolane as a biosynthetic alternative to D2 diesel, and the first microbial overproduction of bisabolene in Escherichia coli and Saccharomyces cerevisiae,” says Taek Soon Lee, who directs JBEI’s metabolic engineering program and is a project scientist with Lawrence Berkeley National Laboratory (Berkeley Lab)’s Physical Biosciences Division. “This work is also a proof-of-principle for advanced biofuels research in that we’ve shown that we can design a biofuel target, evaluate this fuel target, and produce the fuel with microbes that we’ve engineered.”
Lee is the corresponding author of a paper reporting this research in the journal Nature Communications entitled  “Identification and microbial production of a terpene-based advanced biofuel.”
“We desperately need drop-in, renewable biofuels that can directly replace petroleum-derived fuels, particularly for vehicles that cannot be electrified,” says co-author Keasling, CEO of JBEI and a leading authority on advanced biofuels. “The technology we describe in our Nature Communications paper is a significant advance in that direction.”
“Sesquiterpenes have a high-energy content and physicochemical properties similar to diesel and jet fuels,” Lee says. “Although plants are the natural source of terpene compounds, engineered microbial platforms would be the most convenient and cost-effective approach for large-scale production of advanced biofuels.”
In earlier work, Lee and his group engineered a new mevalonate pathway (a metabolic reaction critical to biosynthesis) in both E. coli and S. cerevisiae that resulted in these two microorganisms over-producing a chemical compound called farnesyl diphosphate (FPP), which can be treated with enzymes to synthesize a desired terpene. In this latest work, Lee and his group used that mevalonate pathway to create bisabolene, which is a precursor to bisabolane.
“We proposed that the generality of the microbial FPP overproduction platforms would allow for the biosynthesis of sesquiterpenes,” Lee says. “Through multiple rounds of large-scale preparation in shake flasks, we were able to prepare approximately 20 milliliters of biosynthetic bisabolene, which we then hydrogenated to produce bisabolane.”
“Bisabolane has properties almost identical to D2 diesel but its branched and cyclic chemical structure gives it much lower freezing and cloud points, which should be advantageous for use as a fuel,” Lee says. “Once we confirmed that bisabolane could be a good fuel, we designed a mevalonate pathway to produce the precursor, bisabolene. This was basically the same platform used to produce the anti-malarial drug artemisinin except that we introduced a terpene synthase and further engineered the pathway to improve the bisabolene yield both in E. coli and yeast.”
Lee and his colleagues are now preparing to make gallons of bisabolane for tests in actual diesel engines, using the new fermentation facilities at Berkeley Lab’s Advanced Biofuels Process Demonstration Unit. “Once the complete fuel properties of hydrogenated biosynthetic bisabolene can be obtained, we’ll be able to do an economic analysis that takes into consideration production variables such as the cost and type of feedstock, biomass depolymerization method, and the microbial yield of biofuel,” Lee says. “We will also be able to estimate the impact of byproducts present in the hydrogenated commercial bisabolene, such as farnesane and aromatized bisabolene.”
Ultimately, Lee and his colleagues would like to replace the chemical processing step of bisabolene hydrogenation with an alkene reductase enzyme engineered into the E.coli and yeast so that all of the chemistry is performed within the microbes.
This story is reprinted from material from Berkeley Lab, with editorial changes made by Materials Today. The views expressed in this article do not necessarily represent those of Elsevier. Link to original source.